NCT03776812 - Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

178

Participants

Timeline

Start Date

April 5, 2019

Primary Completion Date

March 16, 2021

Study Completion Date

July 12, 2023

Conditions

Recurrent Ovarian CancerRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma

Interventions

DRUG

Relacorilant

Relacorilant is supplied as capsules for oral dosing.

DRUG

Nab-paclitaxel

Nab-paclitaxel is administered as IV infusion over 30-40 minutes.

Trial Locations (24)

1200

Site Reference ID/Investigator #109, Brussels

2650

Site Reference ID/Investigator #119, Edegem

3000

Site Reference ID/Investigator #108, Leuven

10065

Site Reference ID/Investigator #051, New York

Site Reference ID/Investigator #169, New York

Site Reference ID/Investigator #170, New York

15213

Site Reference ID/Investigator #127, Pittsburgh

20141

Site Reference ID/Investigator #122, Milan

22908

Site Reference ID/Investigator #135, Charlottesville

28034

Site Reference ID/Investigator #114, Madrid

Site Reference ID/Investigator #116, Madrid

35249

Site Reference ID/Investigator #004, Birmingham

46009

Site Reference ID/Investigator #113, Valencia

53226

Site Reference ID/Investigator #121, Milwaukee

60637

Site Reference ID/Investigator #001, Chicago

80045

Site Reference ID/Investigator #032, Denver

80131

Site Reference ID/Investigator #112, Napoli

85258

Site Reference ID/Investigator #038, Scottsdale

02215

Site Reference ID/Investigator #106, Boston

Site Reference ID/Investigator #128, Boston

M4N 3M5

Site Reference ID/Investigator #117, Toronto

H2X 0A9

Site Reference ID/Investigator #096, Montreal

00168

Site Reference ID/Investigator #124, Roma

08035

Site Reference ID/Investigator #115, Barcelona